Amneal Pharmaceuticals, Inc. (AMRX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Amneal Pharmaceuticals’s revenue went from $1.0B in fiscal 2016 to $3.0B in fiscal 2025, growth of about 12.8% a year.
Net income in fiscal 2025 was $72M, a net margin of 2.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $3.2B and net income $133M.
Free cash flow was $270M in fiscal 2025 and positive in 8 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B | $2.0B | $1.6B | $1.7B | $1.0B | $1.0B |
| Gross profit | $1.3B | $1.1B | $1.0B | $821M | $785M | $769M | $628M | $353M | $716M | $526M | $597M |
| Operating income | $479M | $394M | $249M | $204M | -$95M | $153M | $91M | -$249M | -$20M | $245M | $285M |
| Net income | $133M | $72M | -$117M | -$84M | -$271M | $13M | $68M | -$604M | -$20M | $0 | $0 |
| EPS (diluted) | $0.42 | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 | — | — |
| R&D | $181M | $186M | $191M | $164M | $196M | $202M | $180M | $188M | $194M | $171M | $179M |
| Revenue growth | — | +8.1% | +16.7% | +8.2% | +5.7% | +5.1% | +22.5% | −2.2% | +60.9% | +1.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $181M | $340M | $295M | $346M | $65M | $242M | $379M | $2M | $250M | $234M | $115M |
| Capital spending | -$92M | -$70M | -$52M | -$43M | -$46M | -$48M | -$56M | -$47M | -$83M | -$95M | -$123M |
| Free cash flow | $88M | $270M | $243M | $302M | $19M | $194M | $323M | -$45M | $167M | $139M | -$8M |
| Dividends paid | — | — | — | — | — | — | $0 | $0 | $183M | $375M | $201M |
| Buybacks | — | — | — | — | — | — | — | — | — | — | $5000 |
| Stock-based pay | $38M | $32M | $28M | $27M | $32M | $28M | $21M | $22M | $168M | $0 | $0 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $282M | $111M | $92M | $26M | $248M | $341M | $151M | $213M | $74M | $27M |
| Debt | — | $2.6B | $2.4B | $2.5B | $2.7B | $2.8B | $2.8B | $2.7B | $2.7B | $1.4B | — |
| Equity | — | -$71M | -$109M | $20M | $298M | $360M | $303M | $232M | $505M | $0 | — |
| Total assets | — | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B | $4.0B | $3.7B | $4.4B | $1.3B | — |
| Shares (diluted) | 336M | 325M | 309M | 176M | 151M | 152M | 149M | 132M | 127M | — | — |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 40.2% | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | 31.5% | 21.7% | 43.1% | 50.9% | 58.7% |
| Operating margin | 15.0% | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% | 23.7% | 28.0% |
| Net margin | 4.2% | 2.4% | -4.2% | -3.5% | -12.2% | 0.6% | 3.4% | -37.1% | -1.2% | 0.0% | 0.0% |
| FCF margin | 2.8% | 8.9% | 8.7% | 12.6% | 0.8% | 9.3% | 16.2% | -2.8% | 10.1% | 13.5% | -0.8% |
| ROIC | — | 14.1% | 8.5% | 6.5% | -2.5% | 3.1% | 2.3% | -6.7% | -0.6% | 16.8% | — |
| ROE | — | -101.8% | 107.0% | -424.6% | -90.7% | 3.6% | 22.4% | -260.2% | -3.9% | — | — |
Frequently asked questions
What is Amneal Pharmaceuticals’s annual revenue?
$3.0B in fiscal 2025 and $3.2B over the twelve months to September 30, 2026.
How much profit does Amneal Pharmaceuticals make?
Net income was $72M in fiscal 2025 (net margin 2.4%).
Is Amneal Pharmaceuticals’s revenue growing?
Yes: revenue rose 8.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.